Clinical Trials Logo

Clinical Trial Summary

This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy and/or immunotherapy in HER2-positive advanced/metastatic gastric/gastroesophageal junction adenocarcinoma patients. The Phase II study was designed to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and/or immunotherapy for advanced/metastatic HER2-positive gastric/gastroesophageal conjunctional adenocarcinoma patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05671822
Study type Interventional
Source Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Contact Wei Shi
Phone +86 13439732857
Email wei.shi@hengrui.com
Status Recruiting
Phase Phase 2
Start date March 14, 2023
Completion date July 30, 2026